Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of ipragliflozin, a selective sodium-glucose co-transporter 2 inhibitor, on blood pressure in Japanese patients with type 2 diabetes mellitus: a pooled analysis of six randomized, placebo-controlled clinical trials.
Kashiwagi A, Yoshida S, Kawamuki K, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Akiyama N, Kondo Y, Ogihara T. Kashiwagi A, et al. Among authors: yoshida s. Diabetol Int. 2016 Sep 9;8(1):76-86. doi: 10.1007/s13340-016-0283-x. eCollection 2017 Mar. Diabetol Int. 2016. PMID: 30603310 Free PMC article.
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Kadokura T, Akiyama N, Kashiwagi A, Utsuno A, Kazuta K, Yoshida S, Nagase I, Smulders R, Kageyama S. Kadokura T, et al. Among authors: yoshida s. Diabetes Res Clin Pract. 2014 Oct;106(1):50-6. doi: 10.1016/j.diabres.2014.07.020. Epub 2014 Jul 26. Diabetes Res Clin Pract. 2014. PMID: 25149596 Clinical Trial.
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Kashiwagi A, Yoshida S, Nakamura I, Kazuta K, Ueyama E, Takahashi H, Satomi H, Kosakai Y, Kawamuki K. Kashiwagi A, et al. Among authors: yoshida s. J Diabetes Investig. 2016 Jul;7(4):544-54. doi: 10.1111/jdi.12471. Epub 2016 Mar 1. J Diabetes Investig. 2016. PMID: 27181576 Free PMC article. Clinical Trial.
Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Saito M, Kaibara A, Kadokura T, Toyoshima J, Yoshida S, Kazuta K, Ueyama E. Saito M, et al. Among authors: yoshida s. Br J Clin Pharmacol. 2019 Aug;85(8):1808-1819. doi: 10.1111/bcp.13972. Epub 2019 Jun 20. Br J Clin Pharmacol. 2019. PMID: 31026084 Free PMC article. Clinical Trial.
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
Lu CH, Min KW, Chuang LM, Kokubo S, Yoshida S, Cha BS. Lu CH, et al. Among authors: yoshida s. J Diabetes Investig. 2016 May;7(3):366-73. doi: 10.1111/jdi.12422. Epub 2015 Oct 14. J Diabetes Investig. 2016. PMID: 27330723 Free PMC article. Clinical Trial.
8,129 results